Theriva Biologics receives FDA Fast Track Designation for VCN-01 in metastatic pancreatic cancer

Theriva Biologics, Inc.

FDA granted Fast Track Designation for VCN-01 combined with gemcitabine/nab-paclitaxel for metastatic pancreatic adenocarcinoma.
VCN-01 is being evaluated in the ongoing Phase 2b VIRAGE trial as first-line therapy for pancreatic ductal adenocarcinoma.
Enrollment in VIRAGE expected to complete in Q3 2024.
Previously, FDA granted orphan drug designation to VCN-01 for PDAC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.